Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway
- 20 January 2023
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 942, 175529
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (19QA1407200)
This publication has 38 references indexed in Scilit:
- A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant TransformationCancer Research, 2013
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInternational Journal of Cancer, 2009
- JAK2/STAT2/STAT3 Are Required for Myogenic DifferentiationJournal of Biological Chemistry, 2008
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJournal of Clinical Investigation, 2007
- Systemic evaluation of total Stat3 and Stat3 tyrosine phosphorylation in normal human tissuesExperimental and Molecular Pathology, 2006
- JAK/STAT signal transduction: Regulators and implication in hematological malignanciesBiochemical Pharmacology, 2006
- What does Stat3 do?Journal of Clinical Investigation, 2002
- Essential Role of STAT3 in the Control of the Acute-Phase Response as Revealed by Inducible Gene Activation in the LiverMolecular and Cellular Biology, 2001